Universal Beteiligungs und Servicegesellschaft mbH Takes Position in ResMed Inc. (NYSE:RMD)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in ResMed Inc. (NYSE:RMD - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 85,443 shares of the medical equipment provider's stock, valued at approximately $19,540,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.06% of ResMed as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in RMD. Mutual Advisors LLC bought a new position in ResMed in the 4th quarter worth approximately $208,000. Kingswood Wealth Advisors LLC bought a new position in ResMed in the 4th quarter worth approximately $236,000. Blue Trust Inc. increased its position in ResMed by 43.1% in the 4th quarter. Blue Trust Inc. now owns 1,394 shares of the medical equipment provider's stock worth $340,000 after buying an additional 420 shares during the period. KBC Group NV increased its position in ResMed by 2.1% in the 4th quarter. KBC Group NV now owns 74,253 shares of the medical equipment provider's stock worth $16,981,000 after buying an additional 1,522 shares during the period. Finally, Pacer Advisors Inc. increased its position in ResMed by 52.3% in the 4th quarter. Pacer Advisors Inc. now owns 44,692 shares of the medical equipment provider's stock worth $10,221,000 after buying an additional 15,345 shares during the period. 54.98% of the stock is owned by institutional investors.

ResMed Price Performance

RMD stock traded down $0.50 during trading on Friday, hitting $244.62. The company had a trading volume of 1,060,298 shares, compared to its average volume of 1,024,582. The company has a fifty day moving average price of $230.20 and a two-hundred day moving average price of $234.21. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The company has a market cap of $35.87 billion, a P/E ratio of 28.88, a P/E/G ratio of 1.53 and a beta of 0.78. ResMed Inc. has a fifty-two week low of $179.42 and a fifty-two week high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating the consensus estimate of $2.36 by $0.01. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. ResMed's quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 EPS. Equities research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's dividend payout ratio is 23.79%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RMD shares. JPMorgan Chase & Co. boosted their price objective on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Piper Sandler lowered their price objective on ResMed from $260.00 to $248.00 and set a "neutral" rating on the stock in a research report on Thursday, April 24th. UBS Group lowered their price objective on ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Wall Street Zen cut ResMed from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $259.33.

Insider Activity at ResMed

In other ResMed news, insider Kaushik Ghoshal sold 9,113 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20. Following the transaction, the insider now owns 9,725 shares of the company's stock, valued at approximately $2,289,265. The trade was a 48.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction on Monday, April 7th. The stock was sold at an average price of $209.85, for a total value of $1,680,688.65. Following the completion of the transaction, the chief executive officer now directly owns 455,472 shares in the company, valued at approximately $95,580,799.20. This represents a 1.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,949 shares of company stock valued at $11,822,260 in the last 90 days. 0.71% of the stock is owned by corporate insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.